Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 16/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243379 | 0.84 | HTR2A (0.63) | HTR2ASCN9AHTR6OPRM1OPRK1 | |
| SCHEMBL15319614 | 0.83 | HTR2A (0.51) | HTR2ASCN9AHTR6 | |
| Hydrochloric Acid SCHEMBL28126599 | 0.83 | HTR2A (0.61) | HTR2ASCN9AHTR6OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL21523197 | 0.82 | HTR2A (0.50) | HTR2ASCN9AHTR6 | |
| SCHEMBL8161027 | 0.82 | GPR84 (0.41) | HTR2AOPRM1OPRL1 | |
| SCHEMBL19064619 | 0.82 | HTR2A (0.53) | HTR2ASCN9AHTR6 | |
| SCHEMBL25295551 | 0.82 | HTR6 (0.55) | HTR6 | |
| SCHEMBL3170619 | 0.79 | ALDH1A1 (0.39) | HTR2A | |
| SCHEMBL21333617 | 0.78 | HTR2A (0.55) | HTR2ASCN9AHTR6 | |
| SCHEMBL25345505 | 0.78 | HTR2A (0.55) | HTR2ASCN9AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092780-A1 | ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD | ANKH LIFE SCIENCES LIMITED (IE) | 2024-03-21 | — | — | US | disclosed |
| WO-2024050395-A1 | ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD | ANKH LIFE SCIENCES LIMITED (IE) | 2024-03-07 | — | — | WO | disclosed |
| CN-105120876-A | Treatment of cancer | BENT REBECCA LAMBERT | 2015-12-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092780-A1 | ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD | DRD2, HNMT, DRD1 | HTR2A 73/4885SCN9A 1626/4885HTR6 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.